Evidence map›Paper›PMID 31665772›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

How Can the Typhoid Fever Surveillance in Africa and the Severe Typhoid Fever in Africa Programs Contribute to the Introduction of Typhoid Conjugate Vaccines?

Hyon Jin Jeon, Justin Im, Andrea Haselbeck, Marianne Holm, Raphaël Rakotozandrindrainy, Abdramane Soura Bassiahi, Ursula Panzner, Ondari D Mogeni, Hye Jin Seo, Octavie Lunguya and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The Severe Typhoid Fever in Africa Program Highlights the Need for Broad Deployment of Typhoid Conjugate Vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 12 countries.

Hyon Jin JeonDepartment of Medicine, University of Cambridge, United Kingdom.
Justin ImInternational Vaccine Institute, Seoul, Republic of Korea.
Andrea HaselbeckInternational Vaccine Institute, Seoul, Republic of Korea.
Marianne HolmInternational Vaccine Institute, Seoul, Republic of Korea.
Raphaël RakotozandrindrainyUniversity of Antananarivo, Madagascar.
Abdramane Soura BassiahiInstitut Supérieur des Sciences de la Population, Université Ouaga II, Ouagadougou, Burkina Faso.
Ursula PanznerInternational Vaccine Institute, Seoul, Republic of Korea.
Ondari D MogeniInternational Vaccine Institute, Seoul, Republic of Korea.
Hye Jin SeoInternational Vaccine Institute, Seoul, Republic of Korea.
Octavie LunguyaInstitut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.
Jan JacobsDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp.
Iruka N OkekeFaculty of Pharmacy, University of Ibadan, Nigeria.
Mekonnen TerferiArmauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia.
Ellis Owusu-DaboSchool of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Gordon DouganDepartment of Medicine, University of Cambridge, United Kingdom.
Megan CareyBill & Melinda Gates Foundation, Seattle, Washington.
A Duncan SteeleBill & Melinda Gates Foundation, Seattle, Washington.
Jerome H KimInternational Vaccine Institute, Seoul, Republic of Korea.
John D Clemensicddr,b, Dhaka, Bangladesh.
Jason R AndrewsStanford University, California.
Se Eun ParkInternational Vaccine Institute, Seoul, Republic of Korea.
Stephen BakerDepartment of Medicine, University of Cambridge, United Kingdom.
Florian MarksDepartment of Medicine, University of Cambridge, United Kingdom.
International Vaccine Institute · KRGates Foundation · USUniversity of Cambridge · GBAll Africa Leprosy Tuberculosis and Rehabilitation Training Centre · ETInstituut voor Tropische Geneeskunde · BEKwame Nkrumah University of Science and Technology · GHNational Institute of Biomedical Research · CDStanford University · USUniversité Ouaga II · BFUniversity of Antananarivo · MGUniversity of California, Los Angeles · USUniversity of Ibadan · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe World Health Organization now recommends the use of typhoid conjugate vaccines (TCVs) in typhoid-endemic countries, and Gavi, the Vaccine Alliance, added TCVs into the portfolio of subsidized vaccines. Data from the Severe Typhoid Fever in Africa (SETA) program were used to contribute to TCV introduction decision-making processes, exemplified for Ghana and Madagascar.

methodsData collected from both countries were evaluated, and barriers to and benefits of introduction scenarios are discussed. No standardized methodological framework was applied.

resultsThe Ghanaian healthcare system differs from its Malagasy counterpart: Ghana features a functioning insurance system, antimicrobials are available nationwide, and several sites in Ghana deploy blood culture-based typhoid diagnosis. A higher incidence of antimicrobial-resistant Salmonella Typhi is reported in Ghana, which has not been identified as an issue in Madagascar. The Malagasy people have a low expectation of provided healthcare and experience frequent unavailability of medicines, resulting in limited healthcare-seeking behavior and extended consequences of untreated disease.

conclusionsFor Ghana, high typhoid fever incidence coupled with spatiotemporal heterogeneity was observed. A phased TCV introduction through an initial mass campaign in high-risk areas followed by inclusion into routine national immunizations prior to expansion to other areas of the country can be considered. For Madagascar, a national mass campaign followed by routine introduction would be the introduction scenario of choice as it would protect the population, reduce transmission, and prevent an often-deadly disease in a setting characterized by lack of access to healthcare infrastructure. New, easy-to-use diagnostic tools, potentially including environmental surveillance, should be explored and improved to facilitate identification of high-risk areas.

Indexed as

Decision Making, OrganizationalGhanaHumansImmunization ProgramsIncidenceMadagascarPreventive Health ServicesSalmonella typhiTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, ConjugateWorld Health OrganizationTyphoid-Paratyphoid VaccinesVaccines, ConjugateGhanaMadagascarmass campaignSalmonella Typhityphoid fevervaccine introduction

Identifiers

PMID31665772
PMCPMC6821306
OpenAlexW2982318575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.